2025
Low Anterior Resection Syndrome Evaluation and Management
Linhares S, Mongiu A. Low Anterior Resection Syndrome Evaluation and Management. Clinics In Colon And Rectal Surgery 2025 DOI: 10.1055/s-0045-1807741.Peer-Reviewed Original ResearchLow anterior resection syndromeTreatment optionsNerve stimulationTreatment of low anterior resection syndromePosterior tibial nerve stimulationSecond-line treatmentThird-line treatmentPelvic floor rehabilitationSphincter-sparing surgeryFirst-line treatmentSacral nerve stimulationPermanent stoma creationTibial nerve stimulationAnterior resection syndromeQuality of lifeMultiple measurement toolsConstellation of symptomsFlatus incontinenceAntegrade enemasFloor rehabilitationRectal cancerTreatment algorithmPreoperative educationStoma creationBowel habitsOutcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population.
Ganguly A, Paladiya R, Ingawale S, Giri S, Abbagoni V, Thumar J. Outcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population. Journal Of Clinical Oncology 2025, 43: 208-208. DOI: 10.1200/jco.2025.43.4_suppl.208.Peer-Reviewed Original ResearchTNT groupTotal neoadjuvant therapyLocally Advanced Rectal CancerAdvanced rectal cancerManagement of locally advanced rectal cancerTumor locationNeoadjuvant therapyConventional therapyRectal cancerCT groupPropensity score matchingLow tumorsHigh tumorNo responsePathologic response to treatmentTreating locally advanced rectal cancerResponse ratePartial response ratePathological response rateScore matchingFisher's exact testResponse to treatmentComplete responseAdjuvant treatmentUnderserved populationsPredictors of late recurrence of colorectal cancer (CRC) among older long-term survivors using claims-based evidence.
Yasin F, Westvold S, Long J, Fan J, Hyslop T, Leeds I, Cecchini M, Gross C, Dinan M. Predictors of late recurrence of colorectal cancer (CRC) among older long-term survivors using claims-based evidence. Journal Of Clinical Oncology 2025, 43: 66-66. DOI: 10.1200/jco.2025.43.4_suppl.66.Peer-Reviewed Original ResearchCRC-specific mortalityAll-Cause MortalityCancer diagnosisColorectal cancerLong-term CRC survivorsNon-cancer related conditionsNon-metastatic colorectal cancerSEER-MedicareRisk of all-cause mortalityRecurrence of colorectal cancerColon cancerSEER-Medicare populationYear 5CRC survivorsSEER-Medicare databaseSurvivorship careRectal cancerFollow-up accountsColorectal cancer recurrenceMultiple co-morbiditiesMedicare claimsRetrospective cohort studyFine-Gray modelEstimate cumulative incidencePrimary risk factor
2024
Pelvic Floor Physical Therapy Prehabilitation (PrePFPT) for the prevention of low anterior resection syndrome
Coppersmith N, Schultz K, Esposito A, Reinhart K, Ray E, Leeds I, Pantel H, Reddy V, Longo W, Mongiu A. Pelvic Floor Physical Therapy Prehabilitation (PrePFPT) for the prevention of low anterior resection syndrome. Surgical Oncology Insight 2024, 1: 100097. DOI: 10.1016/j.soi.2024.100097.Peer-Reviewed Original ResearchLow anterior resection syndromeAnterior resection syndromePelvic floor physical therapyQuality of life outcomesSymptoms of low anterior resection syndromeImprove patient qualityPhysical therapyRectal cancerPrehabilitationDevelopment of low anterior resection syndromeStudy designTreatment of low anterior resection syndromeTreatment of rectal cancerIncidence of low anterior resection syndromeLife outcomesEvaluated pre-Patients' qualityRectal cancer patientsCancer patientsDevelopment of symptomsNeoadjuvant chemoradiotherapyDefecatory dysfunctionImproved recoveryInternational trialsSyndromeAssociation Between Chemotherapy-Induced Peripheral Neuropathy and Low Anterior Resection Syndrome
Linhares S, Schultz K, Coppersmith N, Esposito A, Leeds I, Pantel H, Reddy V, Mongiu A. Association Between Chemotherapy-Induced Peripheral Neuropathy and Low Anterior Resection Syndrome. Cancers 2024, 16: 3578. PMID: 39518019, PMCID: PMC11545659, DOI: 10.3390/cancers16213578.Peer-Reviewed Original ResearchLow anterior resection syndromeChemotherapy-induced peripheral neuropathyAnterior resection syndromeSystemic therapyRectal cancerPeripheral neuropathyAssociated with low anterior resection syndromeRetrospective review of patientsPlatinum-based chemotherapy agentsLow anterior resectionReview of patientsSphincter-preserving surgeryRectal cancer treatmentNeoadjuvant chemoradiationTumor distanceAnal vergeAnterior resectionRetrospective reviewChemotherapy-inducedChemotherapy agentsSide effectsCancer treatmentDebilitating conditionPatientsCIPNShort‐Course TNT Improves Rectal Tumor Downstaging in a Retrospective Study of the US Rectal Cancer Consortium
Bauer P, Gamboa A, Otegbeye E, Chapman W, Rivard S, Regenbogen S, Hrebinko K, Holder‐Murray J, Wiseman J, Ejaz A, Edwards‐Hollingsworth K, Hawkins A, Hunt S, Balch G, Wise P. Short‐Course TNT Improves Rectal Tumor Downstaging in a Retrospective Study of the US Rectal Cancer Consortium. Journal Of Surgical Oncology 2024, 131: 498-506. PMID: 39400312, DOI: 10.1002/jso.27908.Peer-Reviewed Original ResearchLong-course chemoradiationPathological complete responseComplete responseCR rateTumor downstagingConsolidation chemotherapyRate of pathological complete responseNeoadjuvant long-course chemoradiationRate of complete responseClinically node-negative diseaseClinical complete responseShort-course radiationNode-negative diseaseSingle-center reviewMulti-institutional experiencePredictors of CRRAPIDO trialTNT patientsLow tumorsRectal adenocarcinomaRectal cancerNonoperative managementRetrospective studyCancer care centerNonoperative optionsCharting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification
Jain A, Morris M, Berardi D, Arora T, Domingo-Almenara X, Paty P, Rattray N, Kerekes D, Lu L, Khan S, Johnson C. Charting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification. Molecular Cancer 2024, 23: 211. PMID: 39342363, PMCID: PMC11438248, DOI: 10.1186/s12943-024-02133-5.Peer-Reviewed Original ResearchConceptsRectal cancerNormal mucosaMetabolite abundancePatient-matched tumorTumor-specific metabolitesMetabolic heterogeneityPatient survivalRectosigmoid colonSigmoid colonAnatomic subsitePatient-matched normal mucosaTransverse colonMetabolomic profilesAscending colonCRC biomarkersMetabolome DatabaseDescending colonMetabolite changesLeft-sidedRight-sidedColorectumRisk factorsMetabolome mapCancerTumorIntegration of observational and causal evidence for the association between adiposity and 17 gastrointestinal outcomes: An umbrella review and meta‐analysis
Kim M, Lee I, Natarajan P, Do R, Kwon Y, Shin J, Solmi M, Kim J, Won H, Park S. Integration of observational and causal evidence for the association between adiposity and 17 gastrointestinal outcomes: An umbrella review and meta‐analysis. Obesity Reviews 2024, 25: e13823. PMID: 39233338, DOI: 10.1111/obr.13823.Peer-Reviewed Original ResearchConceptsBody mass indexMendelian randomizationPublic health policiesUmbrella reviewStandard deviation increaseUpper GI conditionsGI diseasesHealth policyEpidemiological researchGI conditionsSystematic reviewMass indexMeta-analysesObservational studyDeviation increaseIncreased riskMeta-analysisObesityGastrointestinal outcomesGastrointestinal (GI) diseasesIncreased AdiposityAssociationRectal cancerGallbladder diseaseFatty liver diseaseNCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.
Benson A, Venook A, Adam M, Chang G, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Haste P, Hecht J, Hoffe S, Hunt S, Hussan H, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber J, Sofocleous C, Tavakkoli A, Willett C, Wu C, Jones F, Gurski L. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. Journal Of The National Comprehensive Cancer Network 2024, 22: 366-375. PMID: 39151454, DOI: 10.6004/jnccn.2024.0041.Peer-Reviewed Original ResearchConceptsRectal cancerResponders to neoadjuvant therapyRisk of pelvic recurrenceLocally recurrent rectal cancerEarly-stage rectal cancerNonoperative management approachRecurrent rectal cancerDistal rectal cancerNCCN Guidelines InsightsCurative-intent therapyRectal cancer surgeryOptimal treatment planEndoscopic submucosal dissectionQuality of lifePelvic recurrenceNeoadjuvant therapyMultimodal therapyNCCN guidelinesGenitourinary functionPatient selectionPoor prognosisCancer surgeryColon cancerSubmucosal dissectionClinical trialsA single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer
Verma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng Y, Lam W, Liu S, Reddy V, Hochster H, Higgins S. A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Gastrointestinal Oncology 2024, 15: 1050-1059. PMID: 38989411, PMCID: PMC11231844, DOI: 10.21037/jgo-24-23.Peer-Reviewed Original ResearchCirculating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay.
Solar Vasconcelos J, Titmuss E, Navarro F, Abbott C, Chia B, Topham J, Ladua G, Krishnan T, Hegebarth D, Lim H, Gill K, Gill S, Brown C, Ghuman A, Meneghetti A, Renouf D, Schaeffer D, Chen R, Boyle S, Loree J. Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay. Journal Of Clinical Oncology 2024, 42: e15625-e15625. DOI: 10.1200/jco.2024.42.16_suppl.e15625.Peer-Reviewed Original ResearchMolecular residual diseaseCirculating tumor DNARecurrence-free survivalColorectal cancerMRD assaysDetection of molecular residual diseaseLevels of circulating tumor DNAPoor recurrence-free survivalTreated with curative intentDetect circulating tumor DNAProspective cohort of patientsCurative interventionsCurative-intent treatmentCohort of patientsSingle nucleotide variantsStage I-IIISeparation of patientsMRD- patientsMRD testingNeoadjuvant treatmentResidual diseaseClinical recurrenceCurative intentRectal cancerTumor DNAPersonalized risk assessment of new onset depression in long-term cancer survivors.
Taylor M, Westvold S, Long J, Hyslop T, Wang S, Cecchini M, Leapman M, Leeds I, Lustberg M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of new onset depression in long-term cancer survivors. Journal Of Clinical Oncology 2024, 42: e13798-e13798. DOI: 10.1200/jco.2024.42.16_suppl.e13798.Peer-Reviewed Original ResearchHistory of depressionIncidence of depressionCumulative incidence of depressionRisk of developing depressionLong-term survivorsPredictors of depressionCancer survivorsDisease specific factorsCumulative incidenceNon-HispanicHigher risk of developing depressionRectal cancerLong-term cancer survivorsBreast cancer survivorsCensus tract povertyColon cancerEpisodes of bipolar I disorderPrevalence of depressionMean survival time modelsDiagnosis of depressionReceipt of treatmentAssociated with prior historyHormone receptor statusPatients aged <Adjuvant endocrine therapyFactors Associated With Racial and Ethnic Disparities in Locally Advanced Rectal Cancer Outcomes
Shulman R, Deng M, Handorf E, Meyer J, Lynch S, Arora S. Factors Associated With Racial and Ethnic Disparities in Locally Advanced Rectal Cancer Outcomes. JAMA Network Open 2024, 7: e240044. PMID: 38421650, PMCID: PMC10905315, DOI: 10.1001/jamanetworkopen.2024.0044.Peer-Reviewed Original ResearchConceptsPathological complete responseLocally Advanced Rectal CancerSocial determinants of healthRate of pathological complete responseNon-Hispanic black patientsNon-Hispanic white patientsDeterminants of healthNational Cancer DatabaseNeoadjuvant therapyPN0 statusTumor downstagingSocial determinantsEthnic disparitiesRectal cancerCancer DatabaseRates of tumor downstagingWhite patientsLymph node-positive diseaseNon-Hispanic black raceTreatment outcomesBlack patientsAssociated with treatment responseNon-Hispanic blacksNon-Hispanic whitesNode-positive diseaseTotal neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
Wang M, Gwee Y, Lin Z, Yong W, Sundar R, Tan H, Choo J, Tan K, Lieske B, Cheong W, Tan T, Tey J, Chee C, Chan G. Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center. Journal Of Clinical Oncology 2024, 42: 39-39. DOI: 10.1200/jco.2024.42.3_suppl.39.Peer-Reviewed Original ResearchLocally Advanced Rectal CancerTotal neoadjuvant therapyPathological complete responseDisease-free survivalClinical complete responseCircumferential resection marginCycles of XELOXTumor regression gradeCycles of mFOLFOX6Systemic chemotherapyComplete responseR0 resectionRectal cancerRate of clinical complete responseCycles of systemic chemotherapyPathologic complete response rateThreatened circumferential resection marginCircumferential resection margin involvementDisease-free survival ratesWatch-and-wait approachLimitations of retrospective studiesLong-course CRTMedian tumor distanceAdequate organ functionLong-course chemoradiation
2023
The Predictors of Complete Pathologic Response in Rectal Cancer during the Total Neoadjuvant Therapy Era: A Systematic Review
Flom E, Schultz K, Pantel H, Leeds I. The Predictors of Complete Pathologic Response in Rectal Cancer during the Total Neoadjuvant Therapy Era: A Systematic Review. Cancers 2023, 15: 5853. PMID: 38136397, PMCID: PMC10742121, DOI: 10.3390/cancers15245853.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTotal neoadjuvant therapyPathologic complete responseClinical complete responseNeoadjuvant therapyComplete responseSystematic reviewRectal cancerTumor responseClinical stage 2Complete pathologic responseRetrospective cohort studyRandomized clinical trialsHeterogeneity of studiesLevel of evidenceElectronic databases EmbaseIdentification of predictorsCancer treatment paradigmLong-term trialsNeoadjuvant chemotherapyTherapy eraPatient demographicsPreoperative predictorsClinical factorsClinicopathologic factorsCohort study
2022
Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer.
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Stadler Z, Yaeger R, Smith J, Saltz L, El Dika I, Crane C, Romesser P, Iyer K, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser M, Schalper K, Diaz L. Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer. Journal Of Clinical Oncology 2022, 40: lba5-lba5. DOI: 10.1200/jco.2022.40.17_suppl.lba5.Peer-Reviewed Original ResearchPD-1 blockadeAdvanced rectal cancerSingle-agent PD-1 blockadeClinical complete responseRectal cancerCo-primary endpointsComplete responseAnti-PD-1 monoclonal antibodyProspective phase II studyPD-1 monoclonal antibodyMismatch repair-deficient colorectal cancersCurative-intent treatmentPhase II studySerious adverse eventsCase of progressionEvidence of tumorDigital rectal examDeficient colorectal cancerMetastatic settingNeoadjuvant chemotherapyAdverse eventsCheckpoint blockadeII studySurgical resectionRectal adenocarcinomaPD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. New England Journal Of Medicine 2022, 386: 2363-2376. PMID: 35660797, PMCID: PMC9492301, DOI: 10.1056/nejmoa2201445.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyDNA Mismatch RepairHumansNeoadjuvant TherapyNeoplasm StagingNeoplasms, Second PrimaryProgrammed Cell Death 1 ReceptorProspective StudiesRectal NeoplasmsRectumTreatment OutcomeConceptsAdvanced rectal cancerClinical complete responsePD-1 blockadeRectal cancerComplete responseSingle-agent PD-1 blockadeAnti-PD-1 monoclonal antibodyProspective phase 2 studyMismatch repair-deficient colorectal cancersDeath-1 blockadePrimary end pointCase of progressionEvidence of tumorPathological complete responsePhase 2 studyDigital rectal examinationDuration of responseMismatch repair deficientMagnetic resonance imagingNeoadjuvant chemotherapyUndergone surgeryAdverse eventsCheckpoint blockadeMetastatic diseaseSurgical resectionPre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative
Chen RC, Garrett-Mayer E, Kamal AH, Makhoul I, Kozlik MMP, Crist STS, Chiang AC, Force O. Pre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative. JCO Oncology Practice 2022, 18: e1367-e1373. PMID: 35353546, DOI: 10.1200/op.21.00455.Peer-Reviewed Original ResearchConceptsQuality Oncology Practice InitiativeRectal cancerTime pointsASCO's Quality Oncology Practice InitiativeNational Comprehensive Cancer Network guidelinesPelvic magnetic resonance imagingNonmetastatic rectal cancerPre-treatment stagingThird of patientsAssessment time pointsRandom-effects modelMagnetic resonance imagingPractice initiativesSubsequent time pointsQuality improvement effortsInitial therapyInitial stagingAppropriate imagingStaging scansNetwork guidelinesUnique patientsOptimal treatmentCare coordinationN stagingEndorectal ultrasoundNonadherence to Multimodality Cancer Treatment Guidelines in the United States
Tchelebi LT, Shen B, Wang M, Potters L, Herman J, Boffa D, Segel JE, Park HS, Zaorsky NG. Nonadherence to Multimodality Cancer Treatment Guidelines in the United States. Advances In Radiation Oncology 2022, 7: 100938. PMID: 35469182, PMCID: PMC9034283, DOI: 10.1016/j.adro.2022.100938.Peer-Reviewed Original ResearchGuideline-concordant treatmentAnal cancerMultimodality treatmentRectal cancerCervical cancerLung cancerAdvanced non-small cell lung cancerNasopharynx cancerNon-small cell lung cancerNonmetastatic anal cancerNational Cancer DatabasePercent of patientsAdvanced cervical cancerCancer treatment guidelinesCell lung cancerMultivariable logistic regressionPrimary tumor siteLow-volume facilitiesTreatment guidelinesComorbid conditionsCancer DatabaseOdds ratioNational guidelinesPatientsConfounding variablesMinimally Invasive Endoscopic and Surgical Management of Rectal Neoplasia
Al Ghamdi S, Leeds I, Fang S, Ngamruengphong S. Minimally Invasive Endoscopic and Surgical Management of Rectal Neoplasia. Cancers 2022, 14: 948. PMID: 35205695, PMCID: PMC8869910, DOI: 10.3390/cancers14040948.Peer-Reviewed Original ResearchRectal neoplasiaRectal cancerImproved survival outcomesLocal recurrence rateAppropriate treatment modalitySurgical management optionsColorectal cancer casesCharacteristic natural historyInvasive endoscopicSurgical managementRecurrence rateSurvival outcomesClinical burdenTreatment modalitiesInvasive treatmentCancer casesWorldwide burdenInterventional endoscopyNatural historyNeoplasiaSuccessful managementEarly detectionCancerOne-thirdMultidisciplinary effort
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply